Lead Sponsor

Pearl Therapeutics, Inc.

Age

40 - 80 years

Sex

ALL

Healthy Volunteers

No

•Signed written informed consent
•40 - 80 years of age
•Clinical history of COPD with airflow limitation that is not fully reversible
•Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods
•Current/former smokers with at least a 10 pack-year history of cigarette smoking
•A measured post- bronchodilator FEV1/FVC ratio of \< or = 0.70
•A measured post- bronchodilator FEV1 \> or = 750ml or 30% predicted and \< or = 80% of predicted normal values
•Able to change COPD treatment as required by protocol

•Women who are pregnant or lactating
•Primary diagnosis of asthma
•Alpha-1 antitrypsin deficiency as the cause of COPD
•Active pulmonary diseases
•Prior lung volume reduction surgery
•Abnormal chest X-ray (or CT scan) not due to the presence of COPD
•Hospitalized due to poorly controlled COPD within 3 months of Screening
•Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)
•Cancer that has not been in complete remission for at least 5 years
•Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives